logo-loader

Geron shares race up in pre-market after FDA news

Last updated: 09:12 31 Oct 2017 EDT, First published: 05:12 31 Oct 2017 EDT

1509455678_shutterstock_444259699
Cancer cells

 

Shares in Geron Corp (NASDAQ:GERN) raced up almost 10% to US$2.26 before the bell in New York on FDA news.

The key Food and Drug Administration (FDA) has granted what's called 'fast track' status to the pharma firm's candidate imetelstat.

The program is designed to expedite the review of new drugs that are intended to treat serious conditions and  can demonstrate the potential to address an unmet medical need.

Imetelstat is used to treat adults with transfusion-dependent anemia due to low or intermediate risk myelodysplastic syndromes (MDS) - a group of cancers.

It is a telomerase inhibitor initially developed by Geron and exclusively licensed to Janssen Biotech Inc. (Janssen) worldwide.

Janssen sponsored the application for Fast Track designation using preliminary data from IMerge, the ongoing clinical trial being conducted by Janssen in lower risk MDS.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 59 minutes ago